SynCore Biotechnology (4192) reported revenue of NT$2 million for Oct 2026, -0.3% year on year and -0.4% from the previous month. Revenue for Jan–Oct 2026 was NT$20.5 million (-5.7% year on year).
In Oct 2026, it ranked No. 143 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$2 million | -0.3% | -0.4% |
| Sep 2026 | NT$2 million | +7.0% | +9.4% |
| Aug 2026 | NT$1.8 million | -12.0% | -15.1% |
| Jul 2026 | NT$2.2 million | -12.3% | +33.6% |
| Jun 2026 | NT$1.6 million | -22.5% | -40.2% |
| May 2026 | NT$2.7 million | -18.7% | +41.7% |
| Apr 2026 | NT$1.9 million | -18.6% | -9.1% |
| Mar 2026 | NT$2.1 million | -4.6% | +13.8% |
| Feb 2026 | NT$1.9 million | +33.9% | -13.5% |
| Jan 2026 | NT$2.1 million | +20.8% | -19.7% |
| Dec 2025 | NT$2.7 million | -12.3% | +0.0% |
| Nov 2025 | NT$2.7 million | +43.7% | +32.5% |
| Oct 2025 | NT$2 million | +20.7% | +6.9% |
| Sep 2025 | NT$1.9 million | +14.5% | -10.0% |
| Aug 2025 | NT$2.1 million | -22.3% | -15.4% |
| Jul 2025 | NT$2.5 million | +164.2% | +18.0% |
| Jun 2025 | NT$2.1 million | +10.3% | -37.3% |
| May 2025 | NT$3.4 million | +79.2% | +41.9% |
| Apr 2025 | NT$2.4 million | -28.6% | +6.5% |
| Mar 2025 | NT$2.2 million | +17.1% | +59.8% |
| Feb 2025 | NT$1.4 million | +59.0% | -22.0% |
| Jan 2025 | NT$1.8 million | +10.5% | -41.7% |
| Dec 2024 | NT$3.1 million | +43.2% | +63.8% |
| Nov 2024 | NT$1.9 million | -13.5% | +11.2% |
| Oct 2024 | NT$1.7 million | -11.7% | +1.5% |
Jan–Oct 2026 cumulative: NT$20.5 million (-5.7% YoY)
Other Biotech & Medical companies
Compare with peers: SynCore Biotechnology vs PEC / SynCore Biotechnology vs Lotus Pharm / SynCore Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16